为推动培育壮大新兴产业和前瞻布局未来产业，7月11日，广东省召开省加快推进现代化产业体系建设 专题会议（人工智能与机器人产业专场），组织有关政府部门、专家学者、各级人大代表和企业代表召 开专题调研座谈会。 在交流发言环节，中国科学院院士、广东省智能科学与技术研究院院长张旭深入阐述了类脑智能 （Brain-inspired Intelligence, BI）作为下一代人工智能的重要发展方向，及其在科技与产业变革中的颠 覆性潜力。 执行统筹：陈杰生 邹琳 吴璇 采写：南都记者 朱唯信 张婷 吴璇 摄影：朱唯信 中国科学院院士、广东省智能科学与技术研究院院长张旭。 类脑智能，是突破AI技术瓶颈的新路径。张旭指出，类脑智能是受脑科学与神经科学启发的智能理论 和技术，其核心在于借鉴生物大脑的低功耗、自进化、小样本学习等优势，构建新型算法、模型与系 统。"类脑智能与现有AI有较大区别，"他解释道，AI依赖数学和计算机科学，而类脑智能从生物脑的 感知认知机制出发，有望实现计算速度、能耗、推理能力的根本性突破。他认为，类脑智能的广义范畴 还包括类脑血管系统、类脑器官工程等前沿领域。例如，通过干细胞诱导分化的类脑器官，可模拟大 ...

金十图示：2025年07月11日（周五）亚盘市场行情 @ JIN10.COM 金十数据 | 一个交易工具 | 现货铂金 XPTUSD | 1361.580 | +1.030 | +0.08% | | --- | --- | --- | --- | | 现货铝金 XPDUSD | 1187.890 | -6.689 | -0.56% | | 黄金(COMEX) GC | 3340.100 | +7.100 | +0.21% | | 白银(COMEX) SI | 37.715 | +0.090 | +0.24% | FOREIGN EXCHANGE 欧元/美元 -0.16% 1.168 EURUSD 英镑/美元 -0.13% 1.356 GBPUSD 美元/日元 IN 146.734 +0.34% USDJPY 澳元/美元 -0.05% 0.659 AUDUSD 美元/瑞郎 +0.07% 0.797 USDCHF | | 纽元/美元 NZDUSD | 0.603 | -0.04% | | --- | --- | --- | --- | | 机 | 英镑/日元 GBPJPY | 198.993 | +0.21% | ...

Core Viewpoint - BP plc is divesting its mobility and convenience, as well as bp pulse businesses in the Netherlands to Catom as part of a $20 billion divestment program aimed at reducing debt and refocusing on fossil fuels [1][2][9]. Group 1: Divestment Details - The divestment is expected to be completed by the end of 2025 and includes around 300 retail sites and 15 active bp pulse EV charging hubs, along with eight additional hubs under development [2][3][9]. - Catom, a rapidly expanding player in the fuel and lubricant distribution sector, will expand its OK retail network to over 400 sites in the Netherlands with this acquisition [4]. Group 2: Strategic Implications - This transaction is part of BP's ongoing portfolio reshaping, which has included divestments in U.S. midstream assets and Canadian oil sands, with a target of generating $3-$4 billion in asset sales by 2025 [5][6]. - The deal reflects a broader trend of consolidation in Europe's downstream sector, where smaller firms like Catom are leveraging scale and adaptability to grow in both fossil fuel and EV infrastructure markets [7]. Group 3: Financial Performance - BP's stock has increased by 17.6% over the past three months, outperforming the industry average growth of 13% [8].

Core Viewpoint - The company Sihuan Pharmaceutical (00460.HK) is pursuing the independent listing of its subsidiary Xuan Zhu Bio-Tech, which has faced challenges in its previous attempts to list on the STAR Market and is now targeting the Hong Kong Stock Exchange for its IPO [1][4]. Group 1: Listing Attempts - Sihuan Pharmaceutical initially planned to spin off Xuan Zhu Bio-Tech for a listing on the STAR Market in March 2022, but the IPO was halted in March 2023 and ultimately withdrawn in May 2024 due to strategic considerations and market conditions [4]. - Following the withdrawal from the A-share market, Sihuan Pharmaceutical initiated a new plan to list Xuan Zhu Bio-Tech on the Hong Kong Stock Exchange, with a second application submitted in June 2024 [4]. Group 2: Product Development - Xuan Zhu Bio-Tech has successfully launched its core product KBP-3571, which is used for treating duodenal ulcers and is expanding its indications to include gastroesophageal reflux disease [6][8]. - The company has over ten drug assets in active development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease [6]. Group 3: Financial Performance - Despite the launch of KBP-3571, Xuan Zhu Bio-Tech reported continuous losses, with projected losses increasing in 2024. Revenue figures for 2023 and 2024 show a significant decline, with losses reported at 300 million yuan for 2023 and 556 million yuan for 2024 [9]. - The company's R&D expenditures have decreased in 2024, with a notable drop in the proportion of R&D spending relative to total operating expenses, attributed to increased administrative and sales expenses [10]. Group 4: Future Outlook - Xuan Zhu Bio-Tech plans to continue investing heavily in the clinical development of its core products, particularly KBP-3571, which is entering Phase III trials, and other products targeting breast cancer and lung cancer [11].

关键点位与操作建议 阻力：3330（通道顶部）、3345/3363 支撑：3300/3283 策略：回调3307-3303分仓做多，止盈70-90点，止损3298。 三色线交易策略 H1三色线维持绿色，H1标准空单（3308附近）已保护性止损出场。日内建议结合M5基础模型短线操作，关注绿色线附近机会。 XAU/USD 黄金 昨日回顾与 ETO Markets 观点 周三黄金呈现V型反转，亚盘延续下跌后于低位震荡，美盘拉升收复失地，日线收下影线偏长小阳线，全天波幅341点。当前行情处于下降通道顶部，若未 突破3330阻力，短期维持震荡下行格局；若突破则看多至3345/3363。市场波动源于贸易谈判不确定性及美联储谨慎政策，ETO Markets 建议重点关注通道顶 部突破信号。 EUR/USD 欧美 昨日回顾与 ETO Markets 观点 周三欧美于1.171附近震荡，波幅40点，日线收小阳线。欧盟与美国贸易谈判进展积极（目标8月前达成协议），美联储会议纪要显示若关税推高通胀，可能 维持更严格政策。ETO Markets 提示需关注欧洲政策变化及美联储官员讲话对市场的潜在影响。 关键点位与操作建议 阻力：1. ...

Core Insights - Companies are increasingly reluctant to invest in HRBP roles, leading to a devaluation of their functions and a reduction in resources allocated to them [1] - The shift in attitude towards functional BPs, including HRBP, reflects a fundamental change where they are seen more as control mechanisms rather than enablers for frontline operations [1] Group 1: Reasons for HRBP Challenges - Reason 1: Many companies assign inexperienced personnel to HRBP roles instead of qualified talent, undermining the effectiveness of HRBP as strategic partners [2] - Reason 2: There is a misalignment in expectations where HRBPs are pressured to prioritize relationship-building over professional expertise, leading to a lack of respect from business units [3] - Reason 3: The absence of data-driven insights limits HRBPs' ability to provide valuable contributions, resulting in their relegation to administrative roles [4] Group 2: Consequences of HRBP Issues - HRBPs often resort to simplistic metrics like revenue per employee, which do not provide meaningful insights for decision-making [5] - The lack of professional depth in HR functions leads to superficial data collection, which fails to address core issues within the organization [6] - When HRBPs operate independently without a cohesive strategy, it can lead to fragmented HR practices and ineffective resource utilization [7]

中国经济网北京7月10日讯 今日，同宇新材（301630）在深交所上市。 同宇新材本次发行募集资金总额为84,000.00万元，募集资金净额为76,037.83万元，拟用于江西同宇新材 料有限公司年产20万吨电子树脂项目（一期）和补充流动资金。 本次发行前，张驰任公司董事长、总经理，直接持有公司1,199.73万股股份，占公司股份总数的 39.99%，同时，张驰为四会兆宇唯一普通合伙人并通过四会兆宇间接控制公司5.26%的表决权。张驰控 制的公司表决权比例合计为45.25%，为公司的控股股东。 张驰和苏世国于2021年12月9日签署了《一致行动协议》，双方确认，自公司2015年12月23日成立至 今，双方作为直接或间接通过第三方持有公司股权的股东，对公司生产经营及其他重大事务决定在事实 上保持一致，对行使公司的股东权利从而依法决定或影响公司的生产经营及其他重大事务在事实上保持 一致，双方作为公司的经营管理决策者的，对公司的生产经营及其他重大事务的依法决定或执行在事实 上保持一致。基于上述事实，自公司成立至今，双方存在事实上一致行动关系。同时，双方约定自协议 签署之日起在公司日常生产经营及其他重大事宜决策等诸方 ...

Group 1 - BP has agreed to sell its mobility and convenience business in the Netherlands, along with BP Pulse, to Catom as part of a $20 billion asset divestment plan [1] - The transaction includes approximately 300 retail sites and 15 operational BP Pulse electric vehicle charging hubs, along with 8 under-construction hubs and related fleet operations in the Netherlands [1] - Catom, established in 1998, is a rapidly growing company in the fuel and lubricants trade, and this acquisition will expand its OK retail network to over 400 strategically located sites in the Netherlands [1] Group 2 - BP's downstream business head, Emma Delaney, stated that the new owner is better suited to advance BP's business in the Netherlands amid the company's restructuring [2] - The transaction is expected to be completed by the end of 2025, pending regulatory approvals [2] - BP previously anticipated asset sales to reach between $3 billion and $4 billion this year [2]

Company Overview - Tongyu New Materials has been deeply engaged in the electronic resin field for nearly 10 years, breaking the monopoly of international leading companies in the lead-free and halogen-free copper-clad laminate applicable electronic resin sector [2] - The company specializes in the research, production, and sales of electronic resins, primarily used in the production of copper-clad laminates, with products including MDI modified epoxy resin, DOPO modified epoxy resin, high-bromine epoxy resin, BPA-type phenolic epoxy resin, and phosphorus-containing phenolic resin curing agents [2] Industry Insights - The electronic resin industry is crucial as it is one of the three main raw materials for producing copper-clad laminates, which are fundamental materials for processing printed circuit boards (PCBs) [2] - The copper-clad laminate industry in mainland China has seen rapid growth, with the output value increasing from $6.1 billion in 2014 to $9.3 billion in 2023, benefiting from the global PCB industry shifting to mainland China [2] Financial Performance - The company achieved operating revenues of 1.193 billion yuan, 886 million yuan, and 952 million yuan for the years 2022, 2023, and 2024, with year-on-year growth rates of 25.95%, -25.70%, and 7.47% respectively [2] - The net profit attributable to the parent company for the same years was 188 million yuan, 164 million yuan, and 143 million yuan, with year-on-year growth rates of 38.98%, -12.51%, and -12.87% respectively [2] - In Q1 2025, the company reported operating revenue of 276 million yuan, a year-on-year increase of 25.60%, while the net profit attributable to the parent company was 33 million yuan, a decrease of 4.43% year-on-year [2] IPO Details - The company plans to issue 10 million new shares in its IPO, raising 840 million yuan, with the funds intended for a 200,000-ton electronic resin project and to supplement working capital [3] - The company is currently experiencing tight production capacity, with utilization rates exceeding 100% during the reporting period [3] Valuation and Market Performance - Tongyu New Materials has a certain valuation advantage, with an issuance price-to-earnings ratio of 23.7 times, compared to an average dynamic P/E ratio of 36.88 times for comparable companies [5] - If the company achieves the average valuation of comparable companies on its first trading day, it would require a 55.6% increase from its issuance price [5] - The issuance price of 84 yuan is relatively high, and similar new stocks with prices around this level have shown an average first-day increase of 85.36%, significantly lower than the average first-day increase of 291.59% for new stocks over the past year [5]

Core Insights - EngageLab participated in The MarTech Summit Hong Kong, a significant event for marketing technology professionals, focusing on trends and innovations in the MarTech industry [1][2] Company Overview - EngageLab is a global leader in customer engagement and marketing technology, providing AI-powered omnichannel solutions that facilitate seamless customer interactions across various channels [8] - The company supports businesses in over 220 countries and regions, delivering more than 1 million messages every second [8] Event Highlights - The summit featured senior marketing executives from renowned brands such as JPMorgan, Yahoo, Nike, and DBS, as well as local enterprises like Cathay Pacific and Hong Kong Disneyland, allowing EngageLab to engage with industry leaders [2] - EngageLab showcased its advanced solutions, including marketing automation and omnichannel communication tools (AppPush, WebPush, Email, SMS, WhatsApp, and OTP), aimed at enhancing customer engagement and driving digital transformation [5][8] Discussions and Opportunities - A senior executive from a leading international airline discussed the challenges and opportunities of implementing an omnichannel engagement strategy with EngageLab, focusing on integrating various communication channels for personalized customer interactions [4] - The airline expressed interest in EngageLab's capabilities in high-concurrency messaging and compliance with data privacy standards for global operations [4] Company Mission - EngageLab aims to empower businesses with scalable and intelligent engagement tools to unlock new opportunities in the digital era, emphasizing innovation and customer-centric growth [6]